RT Journal Article
SR Electronic
T1 From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia
JF Clinical Medicine
JO Clin Med
FD Royal College of Physicians
SP s47
OP s53
DO 10.7861/clinmedicine.18-2-s47
VO 18
IS Suppl 2
A1 Niels Asger Jakobsen
A1 Paresh Vyas
YR 2018
UL http://www.rcpjournals.org/content/18/Suppl_2/s47.abstract
AB The haematological malignancies are a heterogeneous group of neoplastic disorders, which lead to almost 10,000 deaths annually in the UK. Over the past 2 decades, there has been significant progress in our understanding of the pathological mechanisms underlying these cancers, accompanied by improvements in outcomes for some patients. In particular, advances in next-generation sequencing now make it possible to define the genetic lesions present in each patient, which has led to improved disease classification, risk stratification and identification of new therapeutic targets. Here we discuss recent advances in the genomic classification and targeted treatment of haematological malignancies, focusing on acute myeloid leukaemia. Multiple novel drug classes are now on the horizon, including agents that target overactive signalling pathways, differentiation therapies and immunotherapies. By combining molecular diagnostics with targeted therapy, the management of these diseases is set to change radically over the coming years.